Alec Paschalis

2.1k total citations
15 papers, 371 citations indexed

About

Alec Paschalis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Alec Paschalis has authored 15 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Alec Paschalis's work include Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and HER2/EGFR in Cancer Research (3 papers). Alec Paschalis is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and HER2/EGFR in Cancer Research (3 papers). Alec Paschalis collaborates with scholars based in United Kingdom, United States and Belgium. Alec Paschalis's co-authors include Johann S. de Bono, Adam Sharp, Antje Neeb, Stephen R. Plymate, Jonathan Welti, Jun Luo, Ganesh V. Raj, Jon Welti, Juan M. Jiménez‐Vacas and Maria D. Fenor de la Maza and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Clinical Cancer Research.

In The Last Decade

Alec Paschalis

14 papers receiving 369 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alec Paschalis United Kingdom 7 197 163 95 93 40 15 371
Ning Yi Yap Malaysia 10 158 0.8× 157 1.0× 78 0.8× 70 0.8× 20 0.5× 23 358
Li Bie China 13 82 0.4× 211 1.3× 83 0.9× 60 0.6× 12 0.3× 30 557
Adrian Anghel United States 8 102 0.5× 182 1.1× 27 0.3× 166 1.8× 65 1.6× 13 420
Britt Elmedal Laursen Denmark 12 96 0.5× 115 0.7× 60 0.6× 74 0.8× 11 0.3× 28 343
G. Villanova France 8 160 0.8× 121 0.7× 60 0.6× 135 1.5× 20 0.5× 28 447
Matthew McFarlane United States 9 73 0.4× 210 1.3× 52 0.5× 98 1.1× 24 0.6× 16 500

Countries citing papers authored by Alec Paschalis

Since Specialization
Citations

This map shows the geographic impact of Alec Paschalis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alec Paschalis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alec Paschalis more than expected).

Fields of papers citing papers by Alec Paschalis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alec Paschalis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alec Paschalis. The network helps show where Alec Paschalis may publish in the future.

Co-authorship network of co-authors of Alec Paschalis

This figure shows the co-authorship network connecting the top 25 collaborators of Alec Paschalis. A scholar is included among the top collaborators of Alec Paschalis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alec Paschalis. Alec Paschalis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Minchom, Anna, et al.. (2025). Treatment-related adverse events of antibody drug-conjugates in clinical trials. Journal of Hematology & Oncology. 18(1). 71–71. 5 indexed citations
2.
Bono, Johann S. de, Juanita Lopez, Anna Minchom, et al.. (2024). Adverse events of patients treated with antibody-drug conjugates in phase 1 clinical trials at the Royal Marsden Drug Development Unit from 2014 to 2024.. Journal of Clinical Oncology. 42(16_suppl). e15020–e15020. 1 indexed citations
3.
Bono, Johann S. de, Simon Lord, Christina Yap, et al.. (2023). 687P A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours. Annals of Oncology. 34. S479–S480. 1 indexed citations
4.
Neeb, Antje, Lorenzo Buroni, Denisa Bogdan, et al.. (2023). Critical role of antioxidant programs in enzalutamide-resistant prostate cancer. Oncogene. 42(30). 2347–2359. 7 indexed citations
5.
Guo, Christina, Simon J. Crabb, Simon Pacey, et al.. (2023). A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(16_suppl). TPS5105–TPS5105. 2 indexed citations
6.
Sheehan, Beshara, Antje Neeb, Lorenzo Buroni, et al.. (2022). Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. Clinical Cancer Research. 28(14). 3104–3115. 22 indexed citations
7.
Paschalis, Alec, Bertrand Tombal, & Johann S. de Bono. (2021). Prostate-specific Membrane Antigen Theranostics for Prostate Cancer Care: A Need to Prove Clinical Utility. European Urology Focus. 7(2). 231–233. 2 indexed citations
8.
Sheehan, Beshara, Christina Guo, Antje Neeb, et al.. (2021). Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. European Urology Focus. 8(5). 1157–1168. 39 indexed citations
9.
Westaby, Daniel, Maria D. Fenor de la Maza, Alec Paschalis, et al.. (2021). A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. The Annual Review of Pharmacology and Toxicology. 62(1). 131–153. 78 indexed citations
10.
Paschalis, Alec, Beshara Sheehan, Ruth Riisnaes, et al.. (2019). PSMA heterogeneity and DNA repair defects in prostate cancer.. Journal of Clinical Oncology. 37(15_suppl). 5002–5002. 1 indexed citations
11.
Paschalis, Alec, Adam Sharp, Jonathan Welti, et al.. (2018). Alternative splicing in prostate cancer. Nature Reviews Clinical Oncology. 15(11). 663–675. 135 indexed citations
12.
Cave, Judith, et al.. (2018). A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Supportive Care in Cancer. 26(10). 3337–3351. 42 indexed citations
13.
Barrero, Maialen, Mattia Rediti, Mateus Crespo, et al.. (2018). Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer.. Journal of Clinical Oncology. 36(15_suppl). 5070–5070. 4 indexed citations
14.
15.
Paschalis, Alec, et al.. (2009). β1-Adrenoceptor distribution in the rat brain: An immunohistochemical study. Neuroscience Letters. 458(2). 84–88. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ning Yi Yap Breakdown of academic impact, for papers by Li Bie Breakdown of academic impact, for papers by Adrian Anghel Breakdown of academic impact, for papers by Britt Elmedal Laursen Breakdown of academic impact, for papers by G. Villanova Breakdown of academic impact, for papers by Matthew McFarlane
Rankless by CCL
2026